Walk-Away Nation
The Pharmacy Counter Is Breaking Your Benefits Something is happening at the pharmacy counter. Patients are walking up, hearing a number, and walking away. No prescription filled. No therapy started. No one in the system any the wiser. It is happening at scale. A study published this month by Buzz Health found that 49% of […]
The Prescription Your Benefits Budget Already Paid For
Your employees walk away from the pharmacy counter every day with prescriptions they never fill. You already covered the office visit. You already negotiated the benefit. The drug is sitting on a shelf somewhere, waiting. And the cost of whatever happens next lands squarely on your plan.
Specialty Drugs Are Winning. Your Cost Strategy Might Not Be.
A new report from the Pharmaceutical Strategies Group surveyed 228 benefits leaders across employers, health plans, and union coverage. The findings confirm what many plan sponsors already feel: the tools available are not keeping pace with the complexity of the problem.
What Employers Are Talking About at BGH 2026 This Week
The Business Group on Health Annual Conference draws the kind of audience that does not need to be sold on the complexity of employer health benefits. CFOs, benefits leaders, and pharmacy directors arrive already carrying the weight of rising costs, chronic condition management, and the pressure to extract more value from constrained budgets. The 2026 edition, held this week in New Orleans, made clear that those pressures are not easing.
The Biosimilar Savings Are Real.
The biosimilar opportunity is not a rumor. The drugs exist, the FDA has approved them, and the cost differences between a biologic and its biosimilar equivalent are significant. Projections from AJMC put U.S. biosimilar savings between 2021 and 2025 at $38.4 billion and that figure assumes conservative uptake. The ceiling, under stronger adoption conditions, is dramatically higher.
NEBGH Voices Podcast: Pharmacy Trends, GLP‑1s, and Employer Cost Strategy
RazorMetrics Chief Pharmacy Officer Ryan Czado joins NEBGH Voices to discuss GLP-1 therapies, specialty drug costs, biosimilars, and strategies for employers navigating rising pharmacy spend.
The Adherence Gap Brokers Can’t Ignore
By the fourth week of February, the first refill window has closed.
This is where early-year pharmacy performance becomes more predictive than January claims.
Across conditions and geographies, 30 to 50 percent of patients do not take medications as prescribed. A meaningful share never initiate therapy at all. Among those who do start, adherence often declines within weeks. Longitudinal studies show that early adherence patterns tend to persist for years.
Why Employees Struggle With Medications Before Complaints Ever Reach HR
Most benefit leaders don’t hear about medication issues right away. By the time an employee calls HR, the problem has usually been simmering for weeks.
It often starts after the first fill.
When Budgets Tighten, Strategy Matters
At this year’s JPMorgan Healthcare Conference, pharmaceutical executives weren’t talking about growth at any cost. They were talking about containment, recovery, and survival.